• Users Online: 8702
  • Print this page
  • Email this page
Year : 2015  |  Volume : 59  |  Issue : 4  |  Page : 222-227

Comparison of ramosetron with ondansetron for the prevention of post-operative nausea and vomiting in high-risk patients

Department of Anesthesia, Critical Care and Pain, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Aparna S Chatterjee
Department of Anesthesia, Critical Care and Pain, 2nd Floor, Main Building, Tata Memorial Hospital, Dr. E. Borges Marg, Parel, Mumbai - 400 012, Maharashtra
Login to access the Email id

Source of Support: Ramosetron Vials Were Provided by the Company (Cadila Healthcare Ltd.)., Conflict of Interest: None

DOI: 10.4103/0019-5049.154999

Clinical trial registration REF/2012/07/003804

Rights and Permissions

Background and Aims: Post-operative nausea and vomiting (PONV) has an 80% incidence in high-risk patients. This is despite the availability of several antiemetic drugs. Selective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists are considered first-line for prophylaxis, ondansetron being the most commonly used agent. Ramosetron, another selective 5-HT 3 receptor antagonist, is more potent and longer acting than ondansetron. This study was conducted to evaluate the antiemetic efficacy of ramosetron in comparison with ondansetron in patients at a high risk of PONV. Methods: This was a prospective randomised double-blind study carried out over a 6-month period in which 206 patients with at least two risk factors for PONV were randomised to receive ramosetron 0.3 mg or ondansetron 8 mg, 30 min before the end of surgery. The incidence of PONV, severity of nausea and need for rescue antiemetic were recorded over the next 24 h. Primary outcome was the incidence of PONV. Secondary outcomes included severity of nausea and need for rescue. The data were analysed using the Predictive Analytics Software (PASW, version 18: Chicago, IL, USA). Results: The incidence of PONV was found to be 35% in the ramosetron group as opposed to 43.7% in the ondansetron group (P = 0.199). Need for rescue antiemetic was 23.3% in the ramosetron group and 32% in the ondansetron group (P = 0.156) in the 24 h following surgery. Conclusion: Ramosetron 0.3 mg and ondansetron 8 mg were equally effective in reducing the incidence of PONV in high risk patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded719    
    Comments [Add]    
    Cited by others 1    

Recommend this journal